Pirfenidone

Form: Tablet

Strength: 267 mg , 801 mg

Reference Brands: Esbriet®(US & EU)

Category: Respiratory Disorder

Pirfenidone is an FDA- and EMA-approved oral antifibrotic drug used to treat idiopathic pulmonary fibrosis (IPF)—a chronic lung disease marked by progressive scarring of lung tissue. Marketed under the brand name Esbriet, pirfenidone helps slow lung function decline, reduce inflammation, and limit fibrosis by inhibiting pro-fibrotic cytokines like TGF-β. Available in 267 mg and 801 mg tablet strengths, it is usually taken three times daily with food. Pirfenidone improves quality of life and delays disease progression in IPF patients. Common side effects include nausea, rash, and photosensitivity. Regular liver monitoring is advised during treatment.